Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by eGenesis
eGenesis Raises $191 Million Series D Financing to Advance Lead Program for Kidney Transplant
September 04, 2024
From
eGenesis
Via
Business Wire
eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient
March 21, 2024
From
eGenesis
Via
Business Wire
eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan
February 13, 2024
From
eGenesis
Via
Business Wire
eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor
January 18, 2024
From
eGenesis
Via
Business Wire
eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference
October 26, 2023
From
eGenesis
Via
GlobeNewswire
eGenesis Announces Publication in Nature of Landmark Preclinical Data Demonstrating Long-Term Survival with Genetically Engineered Porcine Kidneys
October 11, 2023
From
eGenesis
Via
GlobeNewswire
eGenesis Announces Publication in Nature Communications Characterizing Renal Physiology and Endocrine Function in Non-Human Primates Post Xenograft Transplant
June 13, 2023
From
eGenesis
Via
GlobeNewswire
eGenesis Presents New Data on Long-Term Survival in Preclinical Kidney Xenotransplantation at American Transplant Congress 2023
June 05, 2023
From
eGenesis
Via
GlobeNewswire
eGenesis Announces Knut Niss as Chief Technology Officer
January 24, 2023
From
eGenesis
Via
GlobeNewswire
eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
January 09, 2023
From
eGenesis
Via
GlobeNewswire
Tickers
ELDN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.